Literature DB >> 28321463

[When is surgical resection of the primary tumor indicated in metastatic prostate cancer and what is the scientific rationale?]

J Noldus1.   

Abstract

Similar to other tumour entities, analyses of cancer databases giving hope that patients with advanced prostate cancer with osseous metastases benefit from cytoreductive surgery. Prospective clinical trials are in the process of proving this hypothesis. This review article focuses on molecular genetic pathways and clinical data.

Entities:  

Keywords:  Bone metastasis; Cytoreductive treatment; Lymph nodes; Metastases; Prostatectomy, radical

Mesh：

Year:  2017        PMID： 28321463     DOI： 10.1007/s00120-017-0359-7

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


  14 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.

Authors:  Christian von Bodman; Guilherme Godoy; Daher C Chade; Angel Cronin; Laura J Tafe; Samson W Fine; Vincent Laudone; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

3.  Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7.

Authors:  Daniel Lin
Journal:  Urol Oncol       Date:  2016-11       Impact factor: 3.498

4.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry.

Authors:  Christian Gratzke; Jutta Engel; Christian G Stief
Journal:  Eur Urol       Date:  2014-05-10       Impact factor: 20.096

5.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Authors:  G H Mickisch; A Garin; H van Poppel; L de Prijck; R Sylvester
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

Review 6.  Metastasis as an evolutionary process.

Authors:  Samra Turajlic; Charles Swanton
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

Review 7.  A collective route to metastasis: Seeding by tumor cell clusters.

Authors:  Kevin J Cheung; Andrew J Ewald
Journal:  Science       Date:  2016-04-08       Impact factor: 47.728

Review 8.  [Primary Tumour Treatment in Patients with Metastatic Prostate Cancer].

Authors:  T Steuber; B Beyer
Journal:  Aktuelle Urol       Date:  2016-09-28       Impact factor: 0.658

9.  Tracking the clonal origin of lethal prostate cancer.

Authors:  Michael C Haffner; Timothy Mosbruger; David M Esopi; Helen Fedor; Christopher M Heaphy; David A Walker; Nkosi Adejola; Meltem Gürel; Jessica Hicks; Alan K Meeker; Marc K Halushka; Jonathan W Simons; William B Isaacs; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  J Clin Invest       Date:  2013-10-25       Impact factor: 14.808

Review 10.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.